S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod

Orchestra BioMed Stock Price, News & Analysis (NASDAQ:OBIO)

$7.95
+0.44 (+5.86%)
(As of 12/8/2023 ET)
Compare
Today's Range
$7.31
$7.99
50-Day Range
$4.42
$10.37
52-Week Range
$4.26
$23.39
Volume
48,655 shs
Average Volume
40,557 shs
Market Capitalization
$284.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.50

Orchestra BioMed MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
120.1% Upside
$17.50 Price Target
Short Interest
Bearish
5.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.54) to ($1.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

818th out of 942 stocks

Surgical & Medical Instruments Industry

86th out of 95 stocks


OBIO stock logo

About Orchestra BioMed Stock (NASDAQ:OBIO)

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in patients indicated for a cardiac pacemaker; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

OBIO Stock Price History

OBIO Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Orchestra BioMed Holdings, Inc. (OBIO)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings (OBIO) Gets a Buy from LifeSci Capital
Crude Oil Rises Over 1%; Revance Therapeutics Shares Plummet
Why Shares of Orchestra BioMed Jumped Tuesday
Orchestra, Medtronic Join Forces
Orchestra Biomed Holdings Inc (OBIO)
See More Headlines
Receive OBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/12/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OBIO
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.50
High Stock Price Target
$20.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+120.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-2,730,000.00
Pretax Margin
-22,322.03%

Debt

Sales & Book Value

Annual Sales
$147,000.00
Book Value
($0.62) per share

Miscellaneous

Free Float
N/A
Market Cap
$284.16 million
Optionable
Not Optionable
Beta
0.09
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. David P. Hochman (Age 48)
    Founder, Chairman of the Board of Directors & CEO
    Comp: $790k
  • Mr. Darren R. Sherman (Age 52)
    Founder, President, COO & Director
    Comp: $790k
  • Mr. Andrew Lawrence Taylor M.B.A. (Age 52)
    Chief Financial Officer
  • Ms. Inessa R. Wheeler
    Vice President of Strategy & Marketing
  • Mr. William Reed Little (Age 52)
    Executive VP of Corporate Development & Strategy
  • Dr. Yuval Hay Mika D.Sc
    Ph.D., GM & CTO of Bioelectronic Therapies
  • Dr. George Papandreou Ph.D.
    Senior VP & GM of Focal Therapies
  • Dr. Hans-Peter Stoll M.D.
    Ph.D., Chief Clinical Officer
  • Dr. Avraham Matityahu Fischer M.D. (Age 67)
    Senior Vice President of Medical Affairs & Innovation
  • Mr. Bob Laughner
    Senior Vice President of Regulatory & Quality














OBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Orchestra BioMed stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchestra BioMed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OBIO shares.
View OBIO analyst ratings
or view top-rated stocks.

What is Orchestra BioMed's stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for Orchestra BioMed's stock. Their OBIO share price targets range from $15.00 to $20.00. On average, they expect the company's stock price to reach $17.50 in the next year. This suggests a possible upside of 120.1% from the stock's current price.
View analysts price targets for OBIO
or view top-rated stocks among Wall Street analysts.

How have OBIO shares performed in 2023?

Orchestra BioMed's stock was trading at $9.12 at the beginning of 2023. Since then, OBIO stock has decreased by 12.8% and is now trading at $7.95.
View the best growth stocks for 2023 here
.

When is Orchestra BioMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our OBIO earnings forecast
.

How were Orchestra BioMed's earnings last quarter?

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.01. The business had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.89 million.

Who are Orchestra BioMed's major shareholders?

Orchestra BioMed's stock is owned by many different retail and institutional investors. Top institutional investors include Charles Schwab Investment Management Inc. (0.43%), Northern Trust Corp (0.40%), TD Asset Management Inc (0.26%), Arkadios Wealth Advisors (0.14%), Bank of New York Mellon Corp (0.11%) and The Manufacturers Life Insurance Company (0.11%).

How do I buy shares of Orchestra BioMed?

Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OBIO) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -